---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-043761"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:00:08.100994+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aquestive presents Anaphylm data showing consistent PK/PD regardless of film movement

## Summary
- 87.5% of subjects had no film movement; 12.5% showed movement with no significant PK/PD impact.
- Geometric mean Cmax: 351.14 pg/mL (movement) vs 490.27 pg/mL (no movement); p=0.49.
- Median Tmax was 12 minutes for both groups; comparable to epinephrine injection.
- Data supports Anaphylm as a potential needle-free epinephrine option for anaphylaxis if FDA-approved.

## SEC filing metadata
- accession: 0001628280-24-043761
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/0001628280-24-043761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/aqst-20241025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-043761
- JSON: https://secwatch.observer/filing/0001628280-24-043761.json
- Plain text: https://secwatch.observer/filing/0001628280-24-043761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.